Paradigm Biocapital Advisors LP

NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$5.03B2026 Q3
Positions30
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.77.6%

Paradigm Biocapital Advisors LP reported 30 positions worth $5.03B as of September 30, 2026 (13F filed November 16, 2026). Largest holding: RVMD (25.4%). Biggest move: exit NUVLEUR ($731.7M).

10 / 30 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 RVMDRevolution Medicines$1.28B25.38%6,219,323——-18.7%
▸ 2 GMABGenmab A/S$504.3M10.03%14,136,472———
▸ 3 EWTXEdgewise Therapeutics$437.6M8.70%10,778,665——+7.6%
▸ 4 SYRESpyre Therapeutics$396.8M7.89%4,457,450——+16.8%
▸ 5 INSMInsmed$307.7M6.12%2,695,977——+7.7%
▸ 6 MBXMBX Biosciences$221.2M4.40%3,772,885——-9.4%
▸ 7 ORKAOruka Therapeutics$207.7M4.13%2,493,507——+19.1%
▸ 8 BLTEBelite Bio$194.0M3.86%1,142,123——-4.3%
▸ 9 TARSTarsus Pharmaceuticals$180.9M3.60%2,301,375——+2.1%
▸ 10 TNGXTango Therapeutics$173.7M3.45%6,961,546——-3.1%

Pro Feature

The remaining 20 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Paradigm Biocapital Advisors LP hold as of Q3 2026?

Paradigm Biocapital Advisors LP reported 30 positions worth $5.03B in its Q3 2026 13F filing. Largest positions: RVMD (25.4%), GMAB (10.0%), EWTX (8.7%), SYRE (7.9%) and INSM (6.1%).

What did Paradigm Biocapital Advisors LP buy in Q3 2026?

New positions: BBIO, OBX, GPCR, MANE and ORIC (8 in all). Added to: INSM, MBX, SYRE, JBIO and TYRA (13 in all).

What did Paradigm Biocapital Advisors LP sell in Q3 2026?

Reduced: TARS, RVMD, ERAS, VOR and BLTE (6 in all). Sold out entirely: NUVLEUR, APOGEE THERAPEUTICS INC, ALNY, EYPT and MPLT (6 in all).

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.